ALK-Abelló Resultados de beneficios anteriores

Pasado controles de criterios 5/6

ALK-Abelló ha aumentado sus beneficios a una tasa media anual de 67.9%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 10.4% anual. Los ingresos han ido creciendo a una tasa media de 10.4% al año. La rentabilidad financiera de ALK-Abelló es de 10.9%, y sus márgenes netos son de 10.1%.

Información clave

64.6%

Tasa de crecimiento de los beneficios

65.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	12.4%
Tasa de crecimiento de los ingresos	10.3%
Rentabilidad financiera	11.8%
Margen neto	11.2%
Próxima actualización de resultados	23 Aug 2024

Actualizaciones de resultados anteriores recientes

Recent updates

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

May 05

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Apr 27

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 06

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 17

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

Jan 30

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

Dec 05

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

Nov 11

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Sep 01

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Aug 05

We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease

May 12

Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Apr 21

Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?

Mar 31

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

Dec 28

Calculating The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

Dec 07

ALK-Abelló (CPH:ALK B) Has A Rock Solid Balance Sheet

Sep 11

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Aug 21

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero ALK-Abelló. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

CPSE:ALK B Ingresos, gastos y beneficios (DKK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	4,941	555	1,784	590
31 Dec 23	4,824	486	1,753	618
30 Sep 23	4,728	424	1,700	652
30 Jun 23	4,680	359	1,722	664
31 Mar 23	4,590	335	1,702	666
31 Dec 22	4,511	335	1,656	665
30 Sep 22	4,361	333	1,641	658
30 Jun 22	4,227	318	1,586	644
31 Mar 22	4,050	255	1,499	654
31 Dec 21	3,916	219	1,463	630
30 Sep 21	3,808	112	1,442	611
30 Jun 21	3,652	55	1,385	585
31 Mar 21	3,556	66	1,359	516
31 Dec 20	3,491	25	1,363	496
30 Sep 20	3,383	43	1,347	486
30 Jun 20	3,350	49	1,389	489
31 Mar 20	3,363	-9	1,439	480
31 Dec 19	3,274	-50	1,461	466
30 Sep 19	3,178	-183	1,470	425
30 Jun 19	3,100	-200	1,442	385
31 Mar 19	3,030	-149	1,412	377
31 Dec 18	2,915	-170	1,366	360
30 Sep 18	2,891	-183	1,336	395
30 Jun 18	2,897	-152	1,327	399
31 Mar 18	2,873	-136	1,314	410
31 Dec 17	2,910	-158	1,298	426
30 Sep 17	2,901	37	1,233	386
30 Jun 17	2,864	76	1,175	383
31 Mar 17	2,946	149	1,133	383
31 Dec 16	3,005	270	1,091	385
30 Sep 16	2,938	373	1,063	406
30 Jun 16	2,975	396	1,055	412
31 Mar 16	2,767	378	1,038	416
31 Dec 15	2,569	344	1,033	407
30 Sep 15	2,494	221	1,029	399
30 Jun 15	2,349	185	1,018	396
31 Mar 15	2,399	162	1,011	392
31 Dec 14	2,433	181	996	394
30 Sep 14	2,414	205	954	374
30 Jun 14	2,401	188	955	381
31 Mar 14	2,318	127	948	420
31 Dec 13	2,244	61	955	463
30 Sep 13	2,266	6	965	502
30 Jun 13	2,365	53	978	520

Ingresos de calidad: ALK B tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (10.1%) de ALK B son superiores a los del año pasado (7.4%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ALK B ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 67.9% al año.

Acelerando crecimiento: El crecimiento de los beneficios de ALK B en el último año (65.7%) supera su media de 5 años (64.6% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de ALK B en el último año (45.1%) superó al de la industria Pharmaceuticals 3.8%.

ALK-Abelló Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings released

Full year 2023 earnings released

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

First quarter 2023 earnings released

Recent updates

Investor sentiment improves as stock rises 17%

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

Price target increased by 15% to kr.143

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Insider recently sold kr.9.0m worth of stock

Price target increased by 7.8% to kr.121

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

Price target decreased by 7.3% to kr.109

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Price target decreased by 9.2% to kr.116

Investor sentiment deteriorates as stock falls 15%

New major risk - Share price stability

Alk-Abelló A/S Announces Executive Changes

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Price target decreased by 8.5% to kr.129

Investor sentiment deteriorates as stock falls 22%

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

ALK Announces Management Changes

Full year 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Price target decreased to kr.161

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Now 20% undervalued after recent price drop

ALK Begins Clinical Trial Of Its Slit-tablet For The Treatment Of Peanut Allergy

Now 21% undervalued

Alk-Abelló A/S Announces Executive Changes

First quarter 2022 earnings: Revenues exceed analyst expectations

Now 20% undervalued

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease

Less than half of directors are independent

Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?

Desglose de ingresos y gastos
Beta